CD14, Avi-His-Tag, Biotin-Label Recombinant

Only %1 left
Catalog #
101188
As low as $295 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human CD14 molecule, encompassing amino acids 20-336. This construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. 

Synonyms
Monocyte differentiation antigen CD14, Myeloid cell-specific leucine-rich glycoprotein
Product Info
Storage and Usage
Citations
Species
Human
Construct
CD14 (20-336-Avi-His)-(Biotin)
Host Species/Expression System
HEK293
Purity

≥90%

Format

Aqueous buffer solution.

Formulation

8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

MW
37 kDa + glycans
Amino Acids
20-336
Glycosylation
This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank #
NM_000591
UniProt #
P08571
Tag(s)
C-terminal Avi-Tag™, His-Tag
Label

This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation confirmed to be ≥90%.

For more information on enzymatic biotinylation, please see our Tech Note

Background

CD14 (Cluster of Differentiation-14) is a surface antigen expressed predominantly by monocytes and macrophages. It is considered a patterned recognition receptor (PRR), which recognizes pathogen markers. Specifically, CD14 acts as a co-receptor for lipopolysaccharides (LPS) found in the outer membrane of gram-negative bacteria. Through this interaction, CD14 supports initiation of the innate immune response during bacterial infection. CD14 also contributes toward immune responses to viral pathogens such as human respiratory syncytial virus (RSV) and may amplify the inflammatory response observed in severe cases of SARS-CoV-2 infection (COVID-19). Monoclonal antibodies against CD14 are currently undergoing clinical trial as a candidate treatment to limit severe inflammatory responses common in patients hospitalized with COVID-19.